Therapeutic Target
Authors Chekol Abebe E, Mengie Ayele T, Tilahun Muche Z, Asmamaw Dejenie T
Received 19 February 2021
Accepted for publication 19 April 2021
Published 6 May 2021 Volume 2021:15 Pages 143—152
DOI https://doi.org/10.2147/BTT.S307352
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Shein-Chung Chow
Endeshaw Chekol Abebe,1 Teklie Mengie Ayele,2 Zelalem Tilahun Muche,3 Tadesse Asmamaw Dejenie4
1Department of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 2Department of Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 3Department of Medical Physiology, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; 4Department of Medical Biochemistry, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
Correspondence: Endeshaw Chekol Abebe
Department of Medical Biochemistry, College of Health Sciences, Debre Tabor University, PO Box: 272, Debre Tabor, 6300, Ethiopia
, Tel +251 928428133
Email endeshawchekole@gmail.com
Abstract:
The novel coronavirus disease 2019 (COVID-19) pandemic is severely
challenging the healthcare systems and economies of the world, which
urgently demand vaccine and therapy development to combat severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, advancing our
understanding of the comprehensive entry mechanisms of SARS-CoV-2,
especially the host factors that facilitate viral infection, is crucial
for the discovery of effective vaccines and antiviral drugs. SARS-CoV-2
has previously been documented to reach cells by binding with ACE2 and
CD147 receptors in host cells that interact with the spike (S) protein
of SARS-CoV-2. A novel entry factor, called neuropilin 1(NRP1), has
recently been discovered as a co-receptor facilitating the entry of
SARS-CoV-2. NRP1 is a single-pass transmembrane glycoprotein widely
distributed throughout the tissues of the body and acts as a
multifunctional co-receptor to bind with different ligand proteins and
play diverse physiological roles as well as pathological and therapeutic
roles in different clinical conditions/diseases, including COVID-19.
The current review, therefore, briefly provides the overview of
SARS-CoV-2 entry mechanisms, the structure of NRP1, and their roles in
health and various diseases, as well as extensively discusses the
current understanding of the potential implication of NRP1 in SARS-CoV-2
entry and COVID-19 treatment.
Keywords: SARS-COV-2 entry, neuropilin 1, COVID-19, therapeutic target
Neuropilin 1 (NRP1) is one of two homologous neuropilins (NRP) expressed in all vertebrates that has important physiological and pathological roles.1 It was identified first in 1987 by Takagi and his coworkers as a neuronal receptor in developing Chick nervous system.2 NRP1 can exist in two isoforms, namely, secretory and transmembrane isoforms.3,4 The former, also known as truncated or soluble NRP1, circulates freely in the body fluid, whereas the latter isoform, transmembrane NRP1, is a highly conserved single-pass transmembrane protein that interacts with different ligands and has multifaceted functions, including mediating of varieties of physiological and pathological processes; as a result, it is commonly called NRP1.1,3,4
Since its emergence in December 2019, the 2019 coronavirus disease (COVID-19) pandemic, caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been severely challenging the global healthcare systems, economies, and social life.5 COVID-19 is primarily a disease of the respiratory tract typically transmitted from person to person through respiratory droplets and direct contact with SARS-CoV-2 infected individuals or inanimate objects. It is highly infective and transmissive compared to SARS-CoV, as it usually spreads rapidly via active pharyngeal viral shedding.6–8
The global threat of COVID-19 urgently demands extensive efforts to develop vaccines and antiviral therapies that curb the global spread and impact of COVID-19. Thus, growing our extensive knowledge regarding SARS-CoV-2 entry mechanisms is central for designing COVID-19 therapies and vaccines. The entry of SARS-CoV-2 to the host cells requires binding with the host receptors via the viral protein called spike (S) protein.9 Besides ACE2 and CD147, recently, a novel receptor called NRP1 was identified for SARS-CoV-2 entry to the host cell.10,11 Hence, this minireview presents the role of NRP1 in SARS-COV-2 entry and as a possible therapeutic target.
It is the virus–host cell interactions that determine the cellular entry of SARS-CoV-2 and its dissemination across the tissues.12 To infect humans, like SARS-CoV, the S protein of SARS-CoV-2 must first bind to surface receptors of human cells lining the respiratory or intestinal tracts. Once attached, the virus invades the cell then replicates multiple copies of itself. The copies of viruses are then released and lead to the SARS-CoV-2 transmission.12,13
The process of viral attachment to and invasion of human cells occurred using different cellular receptors. Several studies on SARS-CoV-2 entry have so far been carried out mainly on ACE2 and have confirmed that, like SARS-CoV, the S protein of SARS-CoV-2 uses ACE2 as a host surface receptor to enable the virus to enter and infect the cell.10,14–19 In addition to ACE2, CD147 protein has been identified as a co-receptor in host cells to enhance the ability of SARS-CoV-2 to enter human cells, and cause COVID-19 disease.11,14,16,17,20,21
In spite of these entry mechanisms, it was not clearly understood why the tissue tropism of SARS-CoV-2 varies from what is expected from virus–host cell interaction via ACE2 receptor, and why SARS-CoV-2 readily infects tissues other than the respiratory system, such as the brain, heart, and other tissues with no or low ACE2 expression. These raised the possibility that other host factors are required to facilitate virus–host cell interactions in cells with low ACE2 protein level.6,22 Thus, some studies were recently conducted to reveal these unclear mechanisms, and intriguingly, a major breakthrough study by Daly et al as well as a genetic based study by Cantuti-Castelvetri et al and Li and Buck identified a novel receptor called NRP1 that potentially answer the puzzling question what makes SARS-CoV-2 highly infectious and capable of rapidly spreading in human cells.6,22,23 They concluded that NRP1 may serve as an alternative or independent doorway for SARS-CoV-2 entry to and invasion of the human cells.
NRP1, formerly known as A5 protein, is a 120–140 kDa non-tyrosine kinase multifunctional transmembrane heptameric protein with an ATWLPPR sequence consisting of 923 amino acids.1 It is encoded by the NRP1 gene located on the 10p11.22 human chromosome locus and shares 44% amino acid sequence identity with its homology, NRP2.3,4,24
NRP1 comprises a large N-terminus extracellular domain, a relatively very small plasma membrane spanning transmembrane domain, and a short cytoplasmic tail in the inner side of the cell membrane. The extracellular domain in turn comprised of three different subdomains, namely A, B, and C subdomains (Figure 1).1,3 The A or a1-a2 subdomains, also called semaphorin (SEMA) binding subdomains, are located on amino end and contains two complement binding motifs (CUB), namely the complement binding components (C1r and C1s), Uegf (urchin embryonic growth factor), and bone morphogenetic protein 1 (BMP1), whereas the B subdomain involving b1-b2 subdomains are found in the middle of the extracellular domain and are characteristics of clotting factor V and VIII, and discoidin proteins.25–27 This domain is also known as the vascular endothelial growth factors (VEGF) binding subdomain as it serves as a binding site for VEGF.1 The third domain, called C domain, has similarity with MAM (Meprin, A5/NRP1, protein tyrosine phosphatase μ and К) and contributes for homo- or hetero-dimerization of other receptors with the transmembrane domain, thereby affecting distinct downstream signaling cascades.3 The transmembrane domain is a single-pass protein consisting of a conserved GXXXG repeat crossing the cell membrane.27–29 A short domain of NRP1 that contains 43–44 amino acids but lacks tyrosine kinase activity is the cytosolic tail. This domain possesses a PDZ-binding motif that can interact with various proteins such RGS-GAIP-interacting protein (GIPC) and synectin that are essential for via VEGF receptor 2 (VEGFR2) signaling, arterial morphogenesis as well as in maintaining the structural integrity of transmembrane proteins.1,3,27
 |
Figure 1 Schematic diagram of NRP1 Structure. NRP1 contains a large N-terminus extracellular domain comprising A (a1-a2), B (b1-b2), and C subdomains, a very small single-pass plasma membrane spanning TM domain, and a short cytoplasmic domain in the inner side of the cell membrane possessing PDZ-binding motif that can interact with various proteins. The a1/a2/b1 segment binds with SEMA3s, VEGFs, and other proteins, and the C domain involved in receptor dimerization with the TM domain. The b1 of NRP1 binds with S protein of SARS-CoV-2 and facilitate infection. Abbreviations: NRP1, neuropilin 1; SEMA3s, class 3 semaphorin family; TM, transmembrane; VEGFs, vascular endothelial growth factors. |
Although it lacks a direct cellular signaling role, NRP1 is most widely known for its crucial role as a multifunctional co-receptor by forming a complex with other membrane receptors to form holoreceptors.1 Numerous previous studies have shown that NRP1 is a membrane protein that serves as a surface receptor that can bind with wide varieties of protein families, including heparin-binding members of the VEGF family, class 3 members of the SEMA family (SEMA3s) such as SEMA3A, 3C, and 3F, transforming growth factor-β1 (TGF-β1).28,30,31 The SEMA3s are well known to bind to the a1/a2/b1 portion, whereas the VEGFs bind to b1/b2 segments of NRP1. In addition, NRP1 has recently been demonstrated to act as a receptor for extracellular microRNAs, fibroblast growth factor 2 (FGF-2), galectin-1, hepatocyte growth factor (HGF), plexin, β1 integrin, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), hedgehog (Hh), and other growth factors, albeit their binding sites are not well characterized.32,33
Furthermore, a small portion of S protein is currently recognized to be complementary with the b1 domain of human NRP1 protein and allows the binding of SARS-CoV-2 to host cells and hence facilitate infection.6,22
Many studies have pointed out that NRP1 is broadly distributed in the tissues of the human body, with a predominant expression in blood endothelial cells, vascular smooth muscle cells, mesenchymal stem cells, retinal vasculature, neurons, and epithelial cells lining the respiratory and gastrointestinal tracts.1,3,6,22,24 NRP1 has been established to play a myriad of physiological, pathological, and therapeutic roles. As indicated by the plethora of evidence, NRP1 has versatile functions in regulating a wide array of biological processes, such as axon guidance within the central and peripheral nervous systems, angiogenesis, vascular permeability, and cell survival, proliferation, differentiation, migration, and invasion.2,3,30,32
In recent years, NRP1 has also been shown to be expressed by various immune cells, such as macrophages, including alveolar, adipose tissue, bronchial, and vascular macrophages, dendritic cells, T-cells, particularly CD8 cells, regulatory T-cells, B-cells, and mast cells where it controls a multitude of functions, including development, migration, and recruitment, communication between different immune cells, as well as immune system regulation under normal physiological condition.3,4 NRP1 has also been detected in bone cells like osteoclasts and osteoblasts where it has an important role in regulating bone remodeling, for instance osteo-protection through its binding with SEMA3A.3,34,35
Besides, many other studies have improved the understanding of the roles of NRP1 in different pathological conditions, including cancer, immunological disorders, and bone diseases though the molecular mechanisms behind these functions are still to be elucidated.3,33,34 NRP1 is generally overexpressed in various clinical disorders, including malignancies, where it upregulates the oncogenic activities of malignant cells by enhancing cell survival and proliferation, and angiogenesis, as well as by contributing therapeutic resistance.1,3,33
Moreover, NRP1 has been investigated to have a potential role as a therapeutic target in various pathological disorders, for instance in cancer it serves as an antiangiogenic target as well as in cancer and autoimmune diseases it acts as a site for immunotherapies but it needs selective targeting of NRP1 under a particular clinical setting.3,33
Intriguingly, recent encroaching studies have unveiled an additional role of NRP1 in COVID-19 infection, which was found to be a cofactor and facilitator of SARS-CoV-2 entry and could pave the way to a new possible target of intervention for COVID-19.6,22 More recently, an NRP1 receptor was reported in one study as a potential new target for pain inhibitors to treat chronic pain.36 This discovery is based on the grounds of the pain-relieving activity of SARS-CoV-2, which is suggested to mediate the interactions of NRP1 with S-protein by preventing the normal binding of a protein called VEGF-A to NRP1 and blocking pain signals to give pain relief. However, before developing analgesics, more research is required on how NRP1 contributes to pain signaling.
Neuropilin 1 Mediated SARS-CoV-2 Entry Mechanism
According to recent studies, NRP1 is identified as a novel co-receptor as well as a potentiating factor for SARS-CoV-2 entry process by enhancing the interaction of the virus with ACE2 (Table 1).6,22,23,37 Daly et al suggested that it may act as an alternative doorway for SARS-CoV-2 to enter and infect human cells.22 Consistently, the study by Cantuti-Castelvetri et al using tissues from human autopsies revealed that NRP1 significantly potentiates SARS-CoV-2 infectivity.6 Furthermore, this study demonstrated that the NRP1 is expressed strongly in respiratory and olfactory epithelia, while the ACE2 is absent or expressed at low level and hence it may provide an independent gateway for viral entry and invasion of the host cells. Thus, the NRP1 may mediate SARS‑CoV‑2 entry into the brain via the olfactory bulb.6 In agreement with this, a study by Davies et al showed NRP1 is expression in the CNS, involving olfactory‑related regions such as the olfactory tubercles and para-olfactory gyri, suggesting the potential role of NRP1 as an additional mediator of SARS‑CoV‑2 infection implicated in the neurologic manifestations of COVID-19.37 Moreover, one review article has also suggested that the brainstem has a relatively high expression of ACE2 receptor, and possibly NRP1, that SARS-CoV-2 exploits for cell infection. Thus, the respiratory, cardiovascular, gastrointestinal, and neurological functions of the brainstem may be compromised indefinitely as a result of brainstem damage manifested with neurological symptoms even in mild cases of COVID-19 and may results in long-lasting consequences.38 Their abundant expression on epithelia exposed to the external environment as well as their multifaceted functions are the possible reasons that make NRP1 an ideal entry factor for SARS-CoV-2 as well as a critical contributing factor for multisystem involvement of SARS-CoV-2 infection.4,6,22
 |
Table 1 A Summary Table on the Role of NRP1 in SARS-CoV-2 Infection |
SARS-CoV-2 uses a small piece of S protein located on the outer surface of the virus to attach to a complementary region of NRP1 receptors on human cells and hence to penetrate the host cells (Figure 2).6 The cell entry phase of SARS-CoV-2 depends on priming of S protein by host cell proteases.39,40 At the S1/S2 boundary, there is a multi-basic sequence motif called RRAR containing arginine (R) and alanine (A) amino acids, with a sequence of Arg-Arg-Ala-Arg. The RRAR amino acid sequence is a unique feature of SARS-CoV-2 that provides a cleavage site for a host proprotein convertase (furin) and possibly form additional cell surface receptor binding sites and thus enhances pathogenicity by priming the fusion activity.39–41 This is confirmed by another study demonstrating that SARSCoV-2 virus with a natural deletion of the S1/S2 furin cleavage site is associated to attenuated pathogenicity in hamster models.42
 |
Figure 2 The potential NRP1 mediated SARS-CoV-2 entry mechanism into human cells. The trimeric S protein of SARS-CoV-2 binds to host ACE2 via RBM of RBD. Furin mediated cleavage of S protein at S1/S2 site exposes the CendR motif of S1 and enables binding to the b1 subdomain of NRP1. Further processing of S protein by TMPRSS2 on the cell surface (early entry pathway) and CTSL in endolysosome (late entry pathway) exposes the FP and triggers membrane fusion, and the viral RNA get into the host cytoplasm. The genomic RNA undergoes replication and translation to form new SARS-CoV-2 virions after assembly in ERGIC and the new viruses finally released into the outside of the cell. Abbreviations: ACE2, angiotensin converting enzyme 2; CendR, C-end rule; CT, cytoplasmic tail; CTD, C-terminal domain; CTSL, cathepsin L; FP, fusion peptide; HR, heptad repeat; NRP1, neuropilin 1; NTD, N-terminal domain; RBD, receptor binding domain; RBM, receptor binding motif; TM, transmembrane domain; TMPRSS2, TM serine protease 2; ERGIC, endoplasmic reticulum–golgi intermediate compartment. |
The furin protease cuts the full-length S protein into S1 and S2 functional polypeptides and forms a multi-basic RRAR sequence on the carboxyl-terminal of S1 polypeptide. Studies based on x-ray crystallography and biochemical approaches have shown that the S1 C-end rule (CendR) motif is known to directly interact to b1 domain of NRP1 by electrostatic attraction and activate the cell surface receptors.4,6,22 However, even though the CendR peptide of S1 domain is a major recognition site for NRP1, it is not yet known which other segments of NRP1 and the S protein may interact. In addition, a comparable binding between the carboxy-terminal sequence of S1 subunit and NRP1 homolog, NRP2, was also demonstrated.22
A more recent study by Zhenlu and Matthias also indicated that NRP1 facilitate SARS-CoV-2 infection by stimulating the separation of S1 and S2 subunits.23 This study modeled the structures of NRP1 a2/b1/b2 binding to S protein of SARS-CoV-2 and showed NRP1 on binding with S protein trimer bound to an ACE2 dimer. The S1 binds more strongly to the host membrane in the presence of NRP1 and destabilizes the S1/S2 interface and hence increases the likelihood of the S2 subunit to be pulled out rather than S1 being stretched. Thus, NRP1 attachment may stimulate the easier dissociation of S2 from the S1 subunit that triggers membrane fusion and, thus, increase virus infectivity.23
Following the binding of ACE2 and NRP1 with S1 of SARS-CoV-2, further processing of S protein by transmembrane serine protease 2 (TMPRSS2) on the cell surface (early entry pathway) and cathepsin L(CTSL) in endolysosome (late entry pathway) occur. This exposes the fusion peptide (FP) that triggers membrane fusion, and the viral RNA get into the host cytoplasm. Then the genomic RNA undergoes replication and translation to form new virions after assembly in ERGIC, and the new viruses then are released into the outside of the cell.43,44 Previous studies showed that NRPs are known to mediate the internalization of CendR ligands through an endocytosis resembling micropinocytosis but it is unclear whether NRP1 allows attachment and receptor-mediated endocytosis in SARS-CoV-2 infected patients.6,22,45,46 Thus, further studies need to be done to clearly explain the role of NRP1 in the entry and infection mechanisms of SARS-CoV-2.
Inga kommentarer:
Skicka en kommentar